Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:alternativeName |
gptkb:ticilimumab
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States unresectable hepatocellular carcinoma |
| gptkbp:ATCCode |
L01FX18
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:combinationTherapy |
gptkb:durvalumab
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| https://www.w3.org/2000/01/rdf-schema#label |
tremelimumab
|
| gptkbp:mechanismOfAction |
immunotherapy
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue pruritus rash decreased appetite |
| gptkbp:target |
gptkb:CTLA-4
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:CD152
gptkb:Cytotoxic_T-lymphocyte-associated_protein_4 |
| gptkbp:bfsLayer |
7
|